子宮体がんにおける癌・精巣抗原CT45の役割解明とその制御

阐明癌/睾丸抗原CT45在子宫内膜癌中的作用及其调控

• 批准号: 21K09520
• 负责人: 松村 友美子
• 金额: $ 2.66万
• 依托单位: Kyushu Institute of Technology (2022)Kyushu University (2021)
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2021
• 资助国家: 日本
• 起止时间: 2021-04-01 至 2023-03-31
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-21K09520/
• 关键词: 婦人科癌; 癌精巣抗原; 腫瘍免疫

ヒト子宮体がんにおける癌・精巣抗原CT45の機能及び役割を解明する目的に、本年度は以下の研究を遂行して結果を得た。１）九州大学における臨床研究（観察）の承認を取得し、子宮体がん患者の検体の解析を開始した。手術症例の80検体について病理診断により組織型、進行期を分類し、組織をシングルセルにして、フローサイトメトリーによりCT45、PD-L1の発現解析、また三次元培養による機能解析、シングルセル解析のための準備をした。子宮体がんの病期進行に相関してCT45陽性かつPD-L1陽性の分画が増加していることがわかった。２）患者血液からHLA判定をし、作製したMHC class II tetramer２種, MHC class I pentamer１種を用いて、CT45に特異性を持つT細胞の存在を解析した。合わせてPD-1等免疫制御性を有する分子との関連を調べた。進行したがん組織中には、PD-1、CTLA-4, Foxp3陽性の抑制性を持つT細胞が多く確認され、またその中にCT45に特異的なT細胞が存在することがわかった。３）オープンアクセスのThe Cancer Genome Atlas(TCGA)における子宮体がんデータについて、CT45遺伝子およびタンパクの発現と、病期の進行度、生存曲線、遺伝子変異、他の遺伝子との相関、関連するシグナル因子等の解析をした。悪性度に相関してCT45の発現が高いこと、またそれに伴うその他因子の変化を確認することができた。これにより、CT45発現と子宮体がんの進行度との相関性を解析し、臨床的意義を検討することができた。

In this year's study, the results of the following studies have been carried out in this year's study. The cancer and sperm antigen CT45 can be obtained in the study of cancer and sperm antigen in this year. The main results are as follows: 1) the clinical study of Kyushu University (observation) confirms the beginning of the analysis of the patients who were born in Kyushu University. In 80 cases of surgical disease, pathological diagnosis, histological classification, tissue classification, tissue diagnosis, CT45, PD-L1 analysis, three-dimensional training, machine analysis, and laboratory analysis were used. During the period of child disease, the children were divided into two groups: CT45, PD-L1, and so on. 2) the blood samples of the patients were determined by HLA and used as MHC class II tetramer2, and there was an analytical assay in MHC class I pentamer1 and CT45 specific T cells. Immunological responses such as immune response to antiviral drugs, such as PD-1, are characterized by molecular markers. In your organization, PD-1, CTLA-4, Foxp3 sexual inhibitive agents are responsible for confirming that there are many positive cells in the tissue, and that there is a significant difference in the presence of specific CT45 cells in the tissue. 3) to analyze the relationship between The Cancer Genome Atlas (TCGA) and other factors, such as the incidence of disease, the degree of progression of disease, the curve of survival, the number of children, the relationship between each other and other factors, such as the presence of disease, the degree of progression of disease, the curve of survival, the number of children, and so on. In terms of sex, CT45, you can see that you have a high level of sex, and that you have a problem with your other factors. In this article, we can see that there is a difference in the degree of progress of the sub-system, the analysis of the correlation between the two sub-systems, and the meaning of the table. The meaning of the CT45 is different.

项目成果

Tumor-derived ARHGAP35 mutations enhance the Gα13-Rho signaling axis in human endometrial cancer

• DOI: 10.1038/s41417-022-00547-1
• 发表时间: 2022-10-18
• 期刊: CANCER GENE THERAPY
• 影响因子: 6.4
• 作者: Yagi, Hiroshi;Onoyama, Ichiro;Kato, Kiyoko
• 通讯作者: Kato, Kiyoko